Researchers Showcase How AACR Project GENIE is Powering New Insights into Cancer Care

Jun 18

Written By Julie DeSander

Media

Julie DeSander

GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025.

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity